Author:
Thirunavukarasu Deepak,Cheng Lauren Y.,Song Ping,Chen Sherry X.,Borad Mitesh J.,Kwong Lawrence,James Phillip,Turner Daniel J.,Zhang David Yu
Abstract
AbstractWe develop the Oncogene Concatenated Enriched Amplicon Nanopore Sequencing (OCEANS) method, in which variants with low variant allele frequency (VAFs) are amplified and subsequently concatenated for Nanopore Sequencing. OCEANS allows accurate detection of somatic mutations with VAF limits of detection between 0.05 and 1%. We construct 4 distinct multi-gene OCEANS panels targeting recurrent mutations in acute myeloid leukemia, melanoma, non-small- cell lung cancer, and hepatocellular carcinoma and validate them on clinical samples. By demonstrating detection of low VAF single nucleotide variant mutations using Nanopore Sequencing, OCEANS is poised to enable same-day clinical sequencing panels.
Funder
National Institutes of Health
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier A, Cowens J, Cuzick J. Comparison of PAM50 risk of recurrence score with onco type DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Pathol. 2013; 31(22):2783–90.
2. Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov. 2013; 12(5):358–69.
3. Steuer C, Ramalingam S. Tumor mutation burden: leading immunotherapy to the era of precision medicine. J Clin Oncol. 2018; 36(7):631–2.
4. Tie J, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016; 8(346):346ra92.
5. Chabon J, et al. Integrating genomic features for non-invasive early lung cancer detection. Nature. 2020; 580(7802):245–51.
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献